Fidelis Ayebae asked for $12.9 million to keep building Fidson. Investors sent $15.2 million instead

Fidelis Ayebae founded Fidson Healthcare in 1995 with a conviction that Nigeria should manufacture its own medicines rather than import them. Thirty years later, the Nigerian capital market just backed that conviction with N24.65 billion ($15.2 million).

Fidson Healthcare Plc, Nigeria's leading indigenous pharmaceutical manufacturer, has closed its N21 billion ($12.9 million) rights issue at 117% oversubscription, with 3,249 valid applications received for 704.19 million shares valued at N24.65 billion, against the 600 million shares offered at N35 ($0.022) per share.

The Securities and Exchange Commission has approved the full allotment of all 600 million shares. Investors whose applications exceeded their provisional allotments will receive refunds totaling approximately N3.65 billion ($2.25 million).

For Ayebae, who chairs the board and holds the controlling stake in a company he built from the ground up, the oversubscription is a market verdict on what Fidson has become. The company now manages more than 350 registered pharmaceutical brands across multiple therapeutic areas and distributes across Nigeria and West Africa.

Its revenue rose 56% to N93.08 billion ($57.4 million) in its most recently reported period, while operating profit climbed 92% to N16.95 billion ($10.5 million) and profit after tax surged 132% year-on-year, numbers that made the rights issue one of the most straightforward investment cases on the NGX this year.

The offer structure rewarded loyal shareholders. The rights issue was priced at N35 ($0.022) per share, structured as one new ordinary share for every four held by shareholders on the register as at November 12, 2025.

Fidson shares were recently trading at around N136.50 on the Nigerian Exchange, meaning the N35 offer price represented a steep discount to the prevailing market price. That discount, and the quality of the underlying business, drove both rights subscribers and investors seeking additional shares to participate heavily.

Michael Nzewi, chief executive of CardinalStone Partners, the financial adviser and lead issuing house on the transaction, put the share price journey in perspective at the December 2025 signing ceremony. Fidson's previous equity offering in 2019 was priced at N4.50 ($0.003) per share. The N35 offer price in 2025, itself a discount to market, represents a nearly eightfold increase in offering price over six years. "The pricing reflects the company's growth trajectory and the increasing appeal of its shares to investors," Nzewi said.

Managing director and chief executive Biola Adebayo, who has led Fidson's operations since 2022, framed the raise in terms of what comes next. "The additional capital will reinforce our leadership in Nigeria as well as strengthen our footprint across Africa," she said. The proceeds will be deployed across debt repayment to strengthen the balance sheet, capital expenditure on manufacturing infrastructure and working capital to support expanded operations.

The strategic backdrop gives the fundraise weight beyond its financial mechanics. Nigeria continues to rely heavily on imported pharmaceutical products and active pharmaceutical ingredients, creating sustained pressure on foreign exchange demand while exposing the healthcare system to global supply chain disruptions. Ayebae founded Fidson precisely to address that dependency.

Three decades later, the structural problem he identified in 1995 remains one of Nigeria's most pressing industrial challenges. The N21 billion rights issue is, in that sense, both a corporate financing event and a continuation of an argument Ayebae has been making for his entire career.

CardinalStone, which led the transaction from structuring through final allotment, has advised over N5 trillion ($3.1 billion) in capital markets and merger and acquisition transactions and has ranked as the Nigerian Exchange's number-one securities firm by value for four consecutive years from 2022 through 2025.

The rights issue launched on December 19, 2025, and closed on January 30, 2026. The SEC-approved allotment confirmation published this week brings the transaction to its formal close. Ayebae started with a belief that Nigerian hands could make Nigerian medicines. The market just put N21 billion behind that belief.